Opioid mu receptor antagonists - Pipeline Insight, 2024

This “Opioid mu receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Opioid mu receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Opioid mu receptor antagonists Understanding

Opioid mu receptor antagonists: Overview

The µ opioid receptor (MOR) is a prominent member of the G protein-coupled receptor family and the molecular target of morphine and other opioid drugs. Opioid mu receptors consist of a single polypeptide chain possessing an extracellular N-terminal region, seven transmembrane domains, and an intracellular C-terminal tail. The mu opioid antagonists, naloxone and naltrexone are used clinically as rescue medications for opioid related intoxication. The receptor acts as a main pharmacological target for the management of moderate to severe pain, and is of therapeutic value for the treatment of drug abuse, alcohol abuse, and gastrointestinal motility dysfunction. The Opioid mu receptor antagonists based therapies are under investigation for the treatment of opioid induced pruritus of the skin, obesity, and Parkinson-induced tardive dyskinesia.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Opioid mu receptor antagonists R&D. The therapies under development are focused on novel approaches for Opioid mu receptor antagonists.

Opioid mu receptor antagonists Emerging Drugs Chapters

This segment of the Opioid mu receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid mu receptor antagonists Emerging Drugs

FMXIN-001: Nasus Pharma FMXIN001 is a combination drug device using Aptar Pharma's Unidose Powder device. Each single use device contains 4 mg of Naloxone powder. The active compound's shape, size, and morphology in combination with a device provides rapid and precise delivery of the drug to the blood stream. The potential therapy is in Phase II clinical developmental studies for the treatment opioid-relateddisorders.

LT5001: Lumosa Therapeutics LT5001 drug product is a kappa-opioid agonist and partial mu-opioid antagonist and developed as a topical ointment formulation, which is thought to have the potential to modulate peripheral opioid receptors present on sensory nerves and immune cells. The drug is in Phase I/II clinical studies for the treatment of Pruritus.

Opioid mu receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Opioid mu receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Opioid mu receptor antagonists

There are approx. 15+ key companies which are developing the Opioid mu receptor antagonists. The companies which have their Opioid mu receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Nasus Pharma.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Opioid mu receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid mu receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Opioid mu receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid mu receptor antagonists drugs.

Opioid mu receptor antagonists Report Insights

• Opioid mu receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Opioid mu receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Opioid mu receptor antagonists drugs?
• How many Opioid mu receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Opioid mu receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid mu receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid mu receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tonix Pharmaceuticals
• Bridge therapeutics
• ChironWells
• Avior Bio
• Lumosa Therapeutics
• Nasus Pharma
• Orexo
• Progenics Pharmaceuticals
• Trevi Therapeutics
• Chiesi Farmaceutici
• Alkermes
• Shionogi

Key Products

• TNX 601
• BT 219

Research programme: gastrointestinal disorder therapeutics- AV103

• LT-5001
• FMXIN-001
• OX 124
• Methylnaltrexone bromide
• T 111
• Buprenorphine
• ALKS-3831
• Naldemedine

This product will be delivered within 2 business days.